Sermorelin & GHRP-6 Blend – 10MG

€88.00

Size: 10mg
Contents: Sermorelin (5mg) & GHRP-6 (5mg)
Form: Lyophilized powder
Purity: >99%
SKU: Sermorelin-GHRP-6-10mg

Categories: Peptides for Sale, Research Peptides for Sale

Description
Reviews (0)

Sermorelin & GHRP-6 Blend – 10MG – High-Purity Research Peptide

Sermorelin & GHRP-6 Blend – 10MG is a research peptide combination containing 5mg of Sermorelin and 5mg of GHRP-6. The two peptides are studied in relation to growth hormone signalling through different receptor systems, providing researchers with a useful model for investigating pituitary somatotroph activity, growth hormone secretion and interactions between GHRH and growth hormone secretagogue pathways.

Core Peptides lists this formulation as a 10mg lyophilised powder with a stated purity of >99%. Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), while GHRP-6 is a synthetic growth hormone secretagogue associated with the growth hormone secretagogue receptor GHS-R1a.

The combination is intended for research, laboratory, analytical and in-vitro applications only. It is not intended for human or animal consumption, self-administration, diagnosis or treatment of any medical condition.

What Is Sermorelin & GHRP-6 Blend – 10MG?

Sermorelin & GHRP-6 Blend – 10MG combines two structurally different peptides that have been investigated for their roles in growth hormone regulation. The formulation contains equal quantities of each peptide, creating a 1:1 blend of Sermorelin and GHRP-6.

The product contains:

Sermorelin – 5mg: A synthetic 29-amino-acid analogue of GHRH investigated primarily through the classical GHRH receptor.
GHRP-6 – 5mg: A synthetic hexapeptide studied as a growth hormone secretagogue and in relation to GHS-R1a signalling.

According to the current Core Peptides listing, the blend contains 5mg Sermorelin and 5mg GHRP-6, giving a total peptide quantity of 10mg. It is supplied as lyophilised powder and is listed at greater than 99% purity.

Sermorelin & GHRP-6 Blend – 10MG Product Specifications

Specification	Details
Product Name	Sermorelin & GHRP-6 Blend
Total Quantity	10mg
Sermorelin	5mg
GHRP-6	5mg
Blend Ratio	1:1
Form	Lyophilised powder
Listed Purity	>99%
Sermorelin Alternative Name	GRF 1-29 NH₂
GHRP-6 Alternative Names	SKF-110679; growth hormone-releasing hexapeptide
SKU	Sermorelin-GHRP-6-10mg
Intended Use	Research, laboratory and analytical applications

These specifications reflect the current Core Peptides product listing.

What Is Sermorelin?

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of endogenous growth hormone-releasing hormone. It is commonly referred to as GHRH(1-29)-NH₂ or GRF 1-29 NH₂.

Because the N-terminal region of GHRH contains the principal structural features required for interaction with the GHRH receptor, Sermorelin is widely used as a research model for investigating GHRH-mediated signalling in pituitary cells. Core Peptides describes Sermorelin as acting mainly at the classical GHRH receptor on anterior pituitary cells.

Research into GHRH receptor activation has examined intracellular pathways including cyclic AMP (cAMP) and protein kinase A (PKA). These pathways are involved in the cellular regulation of growth hormone synthesis and secretion.

What Is GHRP-6?

GHRP-6 is a synthetic six-amino-acid peptide classified as a growth hormone secretagogue. It is also known by the research designation SKF-110679.

Unlike Sermorelin, GHRP-6 is not a GHRH analogue. It has been investigated primarily through the growth hormone secretagogue receptor 1a (GHS-R1a), a receptor associated with ghrelin signalling. This gives GHRP-6 a distinct pharmacological profile from GHRH-related peptides.

GHRP-6 research has examined its effects on intracellular signalling pathways involving phospholipase C, calcium mobilisation and protein kinase C. These pathways can ultimately converge on the secretory machinery of pituitary somatotroph cells.

How Does the Sermorelin & GHRP-6 Blend Work in Research?

The principal research interest in this blend comes from the fact that Sermorelin and GHRP-6 are associated with different receptor systems.

Sermorelin primarily interacts with the GHRH receptor, whereas GHRP-6 is associated with GHS-R1a. Both receptor systems are expressed in or influence pituitary somatotroph biology, providing researchers with an opportunity to investigate how separate upstream signals can converge on growth hormone-producing cells.

GHRH receptor signalling is commonly associated with cAMP/PKA, while GHS-R1a signalling can involve phospholipase C, intracellular calcium and protein kinase C. The distinct signalling routes make this combination relevant to research into receptor cross-talk and secretory responses.

It is important to distinguish this mechanistic rationale from a proven clinical effect. The exact response to a peptide blend depends on the experimental model, concentrations, timing, biological system and other study parameters.

Sermorelin & GHRP-6 and Pituitary Research

The pituitary gland contains specialised cells called somatotrophs, which are responsible for producing and secreting growth hormone. These cells provide an important model for studying the regulation of the GH axis.

Sermorelin can be used in research examining GHRH receptor activity, while GHRP-6 can be used to investigate GHS-R1a-mediated signalling. Studying the two compounds together may help researchers evaluate how these pathways interact within the same cellular environment.

Potential research endpoints include:

Growth hormone secretion.
GHRH receptor activation.
GHS-R1a receptor signalling.
Intracellular cAMP changes.
Calcium mobilisation.
Protein kinase activity.
Growth hormone secretory patterns.
Downstream GH/IGF-1 axis markers.

Sermorelin and GHRH Receptor Signalling

Sermorelin is primarily investigated through the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells.

Research into GHRH receptor signalling has associated receptor activation with stimulation of adenylate cyclase, increased intracellular cAMP and activation of PKA. These intracellular signals can influence growth hormone synthesis and the mobilisation of secretory vesicles.

This makes Sermorelin useful for controlled laboratory studies investigating the molecular mechanisms involved in GHRH-mediated pituitary signalling.

GHRP-6 and GHS-R1a Signalling

GHS-R1a is a growth hormone secretagogue receptor associated with the physiological actions of ghrelin. GHRP-6 is a synthetic ligand investigated in relation to this receptor system.

Studies of GHS-R1a signalling have examined activation of phospholipase C (PLC), followed by changes involving IP₃, DAG and intracellular calcium. Protein kinase C may also participate in downstream signalling. Core Peptides describes these pathways as distinct from the cAMP/PKA pathway associated with GHRH receptor activation.

Investigating both pathways in the same experimental framework can help researchers examine how different receptor systems influence the same target cell.

Research Into Growth Hormone Secretion

Both Sermorelin and GHRP-6 have been investigated in relation to growth hormone secretion. Research involving Sermorelin has examined changes in GH output following exposure to GHRH(1-29)-related peptides, while GHRP-6 research has investigated its ability to produce pronounced GH secretory responses.

Core Peptides cites research in which GHRP-6 produced substantial growth hormone responses and studies examining GHRP-6 alongside GHRH analogues reported greater responses than either stimulus alone in certain experimental settings. However, some of these studies used full-length GHRH rather than Sermorelin, so their findings should not be presented as direct evidence for this exact commercial blend.

This distinction is important when interpreting the scientific literature and when designing controlled experiments involving Sermorelin and GHRP-6.

Potential Synergy Between Sermorelin and GHRP-6

A major research interest in combining Sermorelin with GHRP-6 is the possibility that stimulating different receptor pathways could produce a distinct or enhanced pituitary response.

Experimental research involving GHRP-6 and GHRH analogues has reported stronger growth hormone responses when the compounds are studied together than when either compound is examined independently. Core Peptides references research showing enhanced GH responses following combined GHRP-6 and GHRH stimulation.

Research specifically combining Sermorelin with GHRP-6 is more limited. Core Peptides cites a study in which Sermorelin and GHRP-6 were included alongside another growth hormone secretagogue, with the researchers observing an increase in serum growth hormone.

Consequently, the concept of synergy provides a useful research hypothesis, rather than a guaranteed outcome of the 10mg commercial formulation.

Sermorelin, GHRP-6 and the GH/IGF-1 Axis

The growth hormone/IGF-1 axis is an interconnected endocrine signalling system involving the hypothalamus, pituitary gland and peripheral tissues.

Growth hormone can influence the production of insulin-like growth factor-1 (IGF-1), making IGF-1 an important downstream marker in studies examining GH-related pathways.

Research cited by Core Peptides has investigated changes in IGF-1 following exposure to Sermorelin-related peptides and growth hormone secretagogues. Such findings can help researchers understand the relationship between upstream peptide signalling, GH secretion and downstream endocrine markers.

However, changes observed in a particular study should not automatically be attributed to the precise Sermorelin & GHRP-6 10mg formulation.

Potential Research Applications

Qualified laboratories may investigate Sermorelin & GHRP-6 Blend – 10MG across a range of peptide and endocrine research areas, including:

GHRH receptor signalling studies.
GHS-R1a receptor research.
Pituitary somatotroph research.
Growth hormone secretion studies.
GH secretory-pulse investigations.
GH/IGF-1 axis research.
Receptor cross-talk investigations.
cAMP and PKA pathway research.
PLC, calcium and PKC signalling studies.
Comparative peptide research.
Structure–activity relationship studies.
In-vitro endocrine research.

Sermorelin & GHRP-6 Chemical Information

Property	Sermorelin	GHRP-6
Common Name	Sermorelin	GHRP-6
Alternative Name	GRF 1-29 NH₂	SKF-110679
Classification	GHRH analogue	Growth hormone secretagogue
Sequence Length	29 amino acids	6 amino acids
Quantity in Blend	5mg	5mg
Blend Ratio	1:1
Physical Form	Lyophilised powder

The supplier identifies Sermorelin as GRF 1-29 NH₂ and GHRP-6 as SKF-110679/growth hormone-releasing hexapeptide.

Why Choose Sermorelin & GHRP-6 Blend – 10MG?

Sermorelin & GHRP-6 Blend – 10MG offers researchers a convenient formulation containing two established peptide research compounds associated with different growth hormone signalling pathways.

10mg total peptide: Contains 5mg Sermorelin and 5mg GHRP-6.
1:1 formulation: Equal quantities of both research peptides.
>99% listed purity: Core Peptides lists the product at greater than 99% purity.
Lyophilised presentation: Supplied as a dry peptide preparation.
Distinct receptor pathways: Combines a GHRH analogue with a GHS-R1a-associated secretagogue.
Established research background: Both peptides have been investigated in pituitary and endocrine research.

Analytical Testing and Research Quality

Laboratories working with peptide research materials may use analytical techniques to confirm identity and evaluate purity. Depending on the research objective, these can include:

High-performance liquid chromatography (HPLC) for chromatographic purity analysis.
Mass spectrometry for molecular-mass and identity confirmation.
Peptide mapping for structural characterisation.
Receptor-binding assays for investigating peptide–receptor interactions.
Cell-based assays for studying biological activity.
Hormone assays for measuring experimental GH or IGF-1 responses.

Researchers should consult the relevant batch-specific Certificate of Analysis and current technical documentation before beginning laboratory work.

Laboratory Handling and Storage

Sermorelin & GHRP-6 Blend – 10MG is supplied as a lyophilised powder. Appropriate handling should follow the supplier’s current technical guidance and the laboratory’s validated procedures for peptide research materials.

Keep the product in its original labelled container.
Protect the lyophilised material from unnecessary moisture exposure.
Follow the current recommended storage conditions supplied with the product.
Minimise unnecessary temperature fluctuations.
Use suitable laboratory protective equipment.
Follow institutional procedures for handling and disposal.
Review batch-specific documentation before experimental use.

Storage requirements can vary according to formulation, packaging and laboratory protocol. The current supplier documentation should take precedence over general storage information.

Frequently Asked Questions About Sermorelin & GHRP-6 Blend – 10MG

What is Sermorelin & GHRP-6 Blend?

It is a research peptide formulation containing 5mg Sermorelin and 5mg GHRP-6, for a total of 10mg. Core Peptides lists it as a lyophilised powder with greater than 99% purity.

What is the ratio of Sermorelin to GHRP-6?

The formulation contains the two peptides in a 1:1 ratio, with 5mg of each peptide.

What is Sermorelin?

Sermorelin is a synthetic 29-amino-acid analogue of GHRH. It is primarily researched in relation to GHRH receptor activity and pituitary growth hormone signalling.

What is GHRP-6?

GHRP-6 is a synthetic hexapeptide studied as a growth hormone secretagogue. It is associated with the GHS-R1a receptor and has a different receptor profile from Sermorelin.

Why are Sermorelin and GHRP-6 studied together?

The two peptides are associated with different receptor systems that can influence pituitary somatotroph activity. Studying them together allows researchers to investigate potential interactions between GHRH receptor and GHS-R1a signalling.

Is there research supporting combined GHRH and GHRP signalling?

Yes. Studies involving GHRH and GHRP-6 have reported enhanced growth hormone responses under particular experimental conditions. However, some studies use full-length GHRH rather than Sermorelin, so the results should not be treated as direct evidence for every Sermorelin and GHRP-6 formulation.

What is the purity of the 10MG blend?

Core Peptides currently lists the Sermorelin & GHRP-6 Blend with a stated purity of >99%.

What form is the product supplied in?

The product is supplied as a lyophilised powder.

What research areas are associated with this blend?

Research areas include pituitary somatotroph biology, GHRH receptor signalling, GHS-R1a research, growth hormone secretion, receptor cross-talk and the broader GH/IGF-1 axis.

Is Sermorelin & GHRP-6 Blend intended for human use?

No. Core Peptides states that its peptide products are intended for research, laboratory or analytical purposes and are not intended for human consumption.

Can this product be used for bodybuilding or athletic performance?

No. This product should not be used for self-administration, bodybuilding or athletic performance. It is intended for appropriate laboratory and research applications only.

Sermorelin & GHRP-6 Blend – 10MG Research Summary

Sermorelin & GHRP-6 Blend – 10MG combines two synthetic research peptides in an equal 1:1 formulation. Each product unit contains 5mg Sermorelin and 5mg GHRP-6, giving a total peptide quantity of 10mg. Core Peptides lists the formulation as a lyophilised powder with greater than 99% purity.

Sermorelin provides a research model for GHRH receptor signalling, while GHRP-6 is investigated primarily in relation to GHS-R1a. These distinct receptor systems provide an experimental framework for studying pituitary signalling, growth hormone secretion and potential receptor cross-talk.

Research involving GHRH and GHRP-6 has reported enhanced GH responses in certain experimental settings. Nevertheless, results vary between studies, and evidence involving full-length GHRH should not automatically be interpreted as evidence for the exact Sermorelin & GHRP-6 10mg formulation.

Research-Use Disclaimer

Sermorelin & GHRP-6 Blend – 10MG is intended solely for qualified research, laboratory, analytical and in-vitro experimental purposes. It is not intended for human or veterinary consumption, self-administration, diagnosis, treatment, cure or prevention of any disease.

References to growth hormone, IGF-1, endocrine signalling or other biological effects describe areas of scientific investigation and should not be interpreted as established clinical benefits or medical advice.

Researchers should review the applicable Certificate of Analysis, product documentation, safety information and relevant legislation before working with this material. Handling, storage and disposal should be performed by appropriately trained personnel using suitable laboratory procedures.

For research use only. Human and animal consumption prohibited.

Product specifications and availability should be verified against the current supplier listing before publication or purchase.

Reviews

There are no reviews yet.